CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade PDS Biotechnology Corporation - PDSB CFD

2.96
12.98%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

PDS Biotechnology Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.62
Open* 2.65
1-Year Change* -59.48%
Day's Range* 2.64 - 2.96
52 wk Range 3.80-10.27
Average Volume (10 days) 684.12K
Average Volume (3 months) 11.14M
Market Cap 133.45M
P/E Ratio -100.00K
Shares Outstanding 31.11M
Revenue N/A
EPS -1.70
Dividend (Yield %) N/A
Beta 1.68
Next Earnings Date Mar 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 2.62 -0.16 -5.76% 2.78 2.88 2.57
Apr 18, 2024 2.87 0.17 6.30% 2.70 2.98 2.66
Apr 17, 2024 2.69 -0.10 -3.58% 2.79 2.79 2.65
Apr 16, 2024 2.77 -0.01 -0.36% 2.78 2.90 2.66
Apr 15, 2024 2.79 -0.38 -11.99% 3.17 3.19 2.78
Apr 12, 2024 3.16 -0.12 -3.66% 3.28 3.36 3.12
Apr 11, 2024 3.34 0.19 6.03% 3.15 3.38 3.15
Apr 10, 2024 3.12 0.02 0.65% 3.10 3.17 3.05
Apr 9, 2024 3.25 -0.03 -0.91% 3.28 3.29 3.07
Apr 8, 2024 3.29 0.06 1.86% 3.23 3.37 3.11
Apr 5, 2024 3.20 -0.01 -0.31% 3.21 3.35 3.15
Apr 4, 2024 3.26 -0.35 -9.70% 3.61 3.68 3.20
Apr 3, 2024 3.65 -0.08 -2.14% 3.73 3.74 3.59
Apr 2, 2024 3.68 -0.18 -4.66% 3.86 3.91 3.61
Apr 1, 2024 3.98 0.00 0.00% 3.98 4.00 3.76
Mar 28, 2024 3.93 0.05 1.29% 3.88 4.53 3.88
Mar 27, 2024 3.80 -0.19 -4.76% 3.99 4.28 3.59
Mar 26, 2024 4.45 -0.29 -6.12% 4.74 4.88 4.45
Mar 25, 2024 4.70 0.18 3.98% 4.52 4.79 4.52
Mar 22, 2024 4.59 -0.21 -4.37% 4.80 4.84 4.54

PDS Biotechnology Corporation Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 PDS Biotechnology Corp Earnings Release
Q1 2024 PDS Biotechnology Corp Earnings Release

Forecast

-

Previous

-
Friday, July 12, 2024

Time (UTC)

13:00

Country

US

Event

PDS Biotechnology Corp Annual Shareholders Meeting
PDS Biotechnology Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 12, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 PDS Biotechnology Corp Earnings Release
Q2 2024 PDS Biotechnology Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0
Total Operating Expense 41.6724 21.4393 14.9024 7.70005 43.0966
Selling/General/Admin. Expenses, Total 12.2414 10.1848 6.96233 8.91149 15.0205
Research & Development 29.431 11.2545 7.92445 6.09958 16.0688
Operating Income -41.6724 -21.4393 -14.9024 -7.70005 -43.0966
Interest Income (Expense), Net Non-Operating -0.38134 0.00435 0.05501 0.31993 -0.55338
Other, Net 0 0
Net Income Before Taxes -42.0538 -21.435 -14.8474 -7.38012 -43.6499
Net Income After Taxes -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income Before Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Income Available to Common Incl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Weighted Average Shares 28.5992 25.5971 16.745 4.86808 1.56211
Diluted EPS Excluding Extraordinary Items -1.42853 -0.66095 -0.88667 -1.43765 -26.1621
Diluted Normalized EPS -1.42853 -0.66095 -0.85692 -2.41384 -21.1658
Total Extraordinary Items 0
Unusual Expense (Income) 0 -7.31102 12.0073
Depreciation / Amortization 0.01561 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 12.6962 9.42241 18.8214 7.2792 7.09265
Selling/General/Admin. Expenses, Total 4.69132 3.57873 2.66627 2.92621 3.33101
Research & Development 8.00485 5.84369 16.1551 4.35299 3.76165
Operating Income -12.6962 -9.42241 -18.8214 -7.2792 -7.09265
Interest Income (Expense), Net Non-Operating -0.24475 -0.23751 -0.14525 0.07455
Net Income Before Taxes -12.9409 -9.65992 -19.1377 -7.42445 -7.01811
Net Income After Taxes -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Net Income Before Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Income Available to Common Excl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Income Available to Common Incl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Diluted Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
Diluted Weighted Average Shares 30.8025 30.428 29.0379 28.4587 28.4516
Diluted EPS Excluding Extraordinary Items -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
Other, Net -0.31633
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 76.4804 66.8402 30.3372 14.4702 35.6511
Cash and Short Term Investments 73.8202 65.2426 28.8396 12.1617 34.6455
Cash & Equivalents 73.8202 65.2426 28.8396 12.1617 34.6455
Prepaid Expenses 2.66023 1.59757 1.49767 2.30846 1.00559
Total Assets 77.0079 67.1979 30.8904 14.4913 36.221
Property/Plant/Equipment, Total - Net 0.52753 0.3577 0.55315 0.02105 0.42695
Property/Plant/Equipment, Total - Gross 0.64295 0.47303 0.66313 0.11542 0.87862
Accumulated Depreciation, Total -0.11542 -0.11533 -0.10998 -0.09437 -0.45166
Other Long Term Assets, Total 0 0.14287
Total Current Liabilities 9.82104 3.75603 3.27045 2.79355 6.38175
Accounts Payable 1.21929 1.3094 1.41522 1.19772 0.39945
Accrued Expenses 8.54514 2.44663 1.85523 1.09764 0.38616
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.05661 0
Other Current Liabilities, Total 0 0.49819 5.59614
Total Liabilities 33.0059 3.98746 3.7608 2.79355 6.38175
Total Long Term Debt 23.1849 0 0 0 0
Long Term Debt 23.0208 0 0
Total Equity 44.002 63.2104 27.1296 11.6977 29.8392
Common Stock 0.00996 0.00939 0.00735 0.00174 0.01059
Additional Paid-In Capital 145.55 123.905 70.9073 40.6337 222.645
Retained Earnings (Accumulated Deficit) -101.558 -60.7036 -43.7851 -28.9377 -192.816
Total Liabilities & Shareholders’ Equity 77.0079 67.1979 30.8904 14.4913 36.221
Total Common Shares Outstanding 30.1703 28.4486 22.2616 5.28124 1.5725
Preferred Stock - Non Redeemable, Net 0
Other Liabilities, Total 0 0.23143 0.49035 0
Capital Lease Obligations 0.16401
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 56.8384 63.3509 67.9734 76.4804 74.4113
Cash and Short Term Investments 54.2514 60.625 65.1994 73.8202 71.6424
Cash & Equivalents 54.2514 60.625 65.1994 73.8202 71.6424
Prepaid Expenses 2.58703 2.72596 2.77399 2.66023 2.76891
Total Assets 57.1878 63.7542 68.4486 77.0079 74.8868
Property/Plant/Equipment, Total - Net 0.34941 0.4033 0.47526 0.52753 0.47542
Total Current Liabilities 9.15383 7.90419 4.12954 9.82104 4.84114
Accounts Payable 5.36656 4.41491 2.07206 1.21929 2.03739
Accrued Expenses 3.73273 3.43598 2.00537 8.54514 2.74248
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 32.704 31.3101 27.4377 33.0059 27.8279
Total Long Term Debt 23.5502 23.4059 23.3081 23.1849 22.9868
Other Liabilities, Total 0 0
Total Equity 24.4838 32.4442 41.0109 44.002 47.0588
Common Stock 0.01023 0.01019 0.01014 0.00996 0.00939
Additional Paid-In Capital 158.076 155.187 152.219 145.55 129.47
Retained Earnings (Accumulated Deficit) -133.602 -122.753 -111.218 -101.558 -82.4207
Total Liabilities & Shareholders’ Equity 57.1878 63.7542 68.4486 77.0079 74.8868
Total Common Shares Outstanding 31.0078 30.8682 30.7236 30.1703 28.4587
Current Port. of LT Debt/Capital Leases 0.05454 0.05331 0.05211 0.05661 0.06127
Long Term Debt 23.4128 23.2544 23.1428 23.0208 22.9097
Capital Lease Obligations 0.1374 0.15151 0.16529 0.16401 0.07713
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Cash From Operating Activities -25.7097 -12.4861 -13.1491 -18.0735 -33.1533
Cash From Operating Activities 0.04908 0.00536 0.01561 0.09841 0.17435
Non-Cash Items 10.6211 4.35124 0.61297 -6.22017 10.9689
Cash Interest Paid 0.85222 0 1.05117
Changes in Working Capital 4.47498 0.07582 1.06967 -4.5716 -3.4285
Cash From Investing Activities 0 29.3815 0
Capital Expenditures 0
Cash From Financing Activities 34.2872 48.8891 29.827 0.75 -20.2688
Financing Cash Flow Items -0.72029 -0.99
Issuance (Retirement) of Stock, Net 10.0075 48.8891 29.827 0.75 0.7212
Issuance (Retirement) of Debt, Net 25 0 -20
Net Change in Cash 8.57754 36.4031 16.6778 12.058 -53.4221
Deferred Taxes 0 -0.38151
Cash Taxes Paid 0
Other Investing Cash Flow Items, Total 0 29.3815
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.65992 -40.8549 -21.7172 -14.2927 -8.47352
Cash From Operating Activities -13.1886 -25.7097 -18.1808 -12.2879 -6.36901
Cash From Operating Activities 0.01411 0.04908 0.0375 0.00009 0.00009
Non-Cash Items 2.26257 10.6211 4.07542 2.59809 1.18923
Changes in Working Capital -5.8054 4.47498 -0.57652 -0.59332 0.9152
Cash From Financing Activities 4.56786 34.2872 24.5806 0.02992 0.00749
Issuance (Retirement) of Stock, Net 4.58852 10.0075 0.02992 0.02992 0.00749
Net Change in Cash -8.62078 8.57754 6.39982 -12.2579 -6.36152
Cash Interest Paid 0.96685 0.85222 0.0625
Financing Cash Flow Items -0.72029 -0.44933
Issuance (Retirement) of Debt, Net -0.02067 25 25

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PDS Biotechnology Corporation Company profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Industry: Bio Therapeutic Drugs

303A College Road East
PRINCETON
NEW JERSEY 08540
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,190.30 Price
+0.930% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

66,925.65 Price
+3.430% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,332.88 Price
-2.500% 1D Chg, %
Long position overnight fee -0.0197%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.40

XRP/USD

0.56 Price
+5.600% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading